Systemic chemotherapy is extensively used in cancer therapy, however for many treatments' response rates are limited. Furthermore, certain regimens are frequently associated with significant morbidity and occasional mortality. Consequently, when alternative options exist, it is desirable to reserve a particular chemotherapy for those patients whose tumours will respond. Therefore, attention is turning to the development of techniques that could provide predictive information regarding a tumour's particular chemosensitivity, as a means of enhancing patient selection for that specific treatment. One approach has been to focus on measures of DNA damage formation and repair as being potentially predictive of cancer cell chemosensitivity, the premise being that higher levels of induced DNA damage (resulting from the chemotherapeutic agents) and/or deficiencies in DNA damage repair are indicative of greater sensitivity. In the present study we have investigated the Comet assay response of a panel of NSCLC cell lines towards cisplatin and found an inverse correlation between sensitivity and damage formation resulting from this agent. Moreover, an inverse correlation was found between resistance and extent of damage repair. Further analysis of multiple alternate cellular end-points (including cell cycle analysis, apoptosis and gene expression changes) revealed cisplatin damage tolerance to be a chemoresistance mechanism in this model system. This study highlights damage tolerance mechanisms as potentially confounding factors in attempts to develop predictive tests based on measures of genotoxicity.
Introduction
Systemic chemotherapy is often used during treatment of cancer patients to cure certain disseminated cancers, decrease tumour volume, alleviate symptoms and prolong life.
Even though chemotherapy has proven to be highly effective in certain tumour types (e.g. testicular cancer) it still suffers from limited response rates in others (e.g. lung cancer).
Moreover, it is frequently associated with significant side effects and even occasional mortality. Consequently, when equally effective treatment options exist, it is desirable to reserve a specific chemotherapy for patients whose tumours will respond. To facilitate this, attention is turning to the development of techniques that could provide predictive information about a tumour's particular chemosensitivity, as a means of enhancing patient selection for that treatment. To date, much research has focused on measures of DNA damage formation and repair as potential predictors of cancer cell chemosensitivity, the premise being that higher levels of induced DNA damage (resulting from the chemotherapeutic agents) and/or deficiencies in DNA damage repair would be indicative/predictive of greater sensitivity.
The chemotherapeutic drug cisplatin is one of the most frequently used agents in cancer treatment (e.g. testicular, ovarian, lung cancer) and its cytotoxic effects are believed to be due to the DNA damage (in the form of crosslinks) it induces in cells. It would therefore be expected that the greater the level of cisplatin adducts present in the tumour tissue of a patient undergoing cisplatin-based chemotherapy, the more likely it is that the tumour cells will die as a result of treatment, with consequent improved patient outcome. In fact, positive correlations between levels of cisplatin-induced DNA crosslinks (in peripheral blood lymphocytes, used as a surrogate tissue) and good clinical outcome have been reported in the literature [1] [2] [3] [4] [5] [6] [7] . However, contradictory results have also been reported [8] [9] [10] . The lack of consensus between these reports indicates that genotoxicity measures may be limited with respect to their predictive potential and may not be suitable in every case. However, a feature common to all of the mentioned studies, and other reports measuring platinum adducts in patients 11, 12 , is the strong interindividual variability in platinum adduct formation, even when patients are subjected to the same cisplatin dose. This may be due to variability in DNA repair. Therefore, measuring repair capacity could potentially predict a patients' response to chemotherapy. Predictive tests of how a tumour would react to a particular chemotherapeutic regimen would be extremely useful as this would permit an individual patient to receive the most appropriate/effective drug(s). Furthermore, such predictive tests could help avoid 4 unnecessary treatments that can have serious side effects, leading to a delay in the effective treatment of the disease.
Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers (the leading site of incidence and cancer mortality worldwide) 13 . The panel of NSCLC cell lines used in the present study comprises the three main histological types of this tumour site with three adenocarcinomas (A549, H522 and H23), one squamous cell carcinoma (H520) and one large cell lung carcinoma (H460). A study by Wistuba et al. 14 indicated that NSCLC cell lines retain the properties of their parental tumours for lengthy culture periods, demonstrating they are representative of the original tumour and, therefore, provide suitable model systems for the study of this neoplasm. Cisplatin-based chemotherapy regimens are often used in treating NSCLC patients, however only around 20% of patients respond to the treatment 15 .
Therefore, in this study we investigated the effect of cisplatin in a panel of five NSCLC cell lines using a series of different end-points (sensitivity/resistance, crosslink formation and repair, cell cycle analysis, apoptosis and gene expression changes) in an attempt to elucidate their potential use in tumour predictive testing.
Results are the average of two independent cultures and are shown as the percentage of viable cells present at 24h compared to the ones present at 0h.
Clonogenic assay for clonal cell survival
Treated and untreated cells were incubated in drug-free media until colonies with over 50 cells could be clearly seen (2 to 4 weeks, depending on the cell line). The colonies were fixed in 100% methanol, stained with a 0.5% solution of crystal violet and counted.
Alkaline Comet Assay
Crosslink formation and repair were determined by the alkaline comet assay (a sensitive microscopy-based method for the detection of a variety of DNA lesions at the level of individual cells) as previously described 16 . Briefly, cisplatin treated and control cells (~1.5×10 4 ) were X-irradiated on ice at 10 Gy (250 kV; 1 Gy / min) then suspended in 0.6% low melting point agarose and dispensed onto a clear microscope slide precoated with 1% 6 normal melting point agarose. Unirradiated controls and cisplatin-treated samples were processed alongside the irradiated samples. Duplicate slides were prepared for each sample.
The cells were lysed overnight at 4 ºC in lysis buffer (2.5 M NaCl, 100 mM Na 2 EDTA, 10 mM Tris-HCl, pH 10.0) containing freshly added 1% Triton X-100. Slides were then washed twice in ice-cold distilled water for 10 min, incubated in ice-cold alkali buffer (300 mM NaOH, 1 mM NaEDTA, pH > 13) for 20 min followed by electrophoresis in the same buffer at 30 V (0.66 V/cm), 300 mA for a further 20 min. The slides were rinsed with neutralization buffer (0.4 M Tris-HCl, pH 7.5) for 20 min followed by washing with ice-cold distilled water for 10 min and left to dry in a 37 ºC incubator. All procedures were carried out on ice and under subdued light.
After drying, slides were stained with a freshly made solution of 2.5 μg/ml propidium 
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Target preparation (cDNA synthesis, in vitro transcription and cRNA fragmentation) and array hybridisation, washing and scanning were performed as described in the Affymetrix GeneChip Expression Analysis Manual 701025 Rev. 3 (Affymetrix, Santa Clara, CA, USA).
High-density DNA oligonucleotide expression arrays (HG-Focus, Affymetrix) containing probes representing around 8,500 well-characterised human genes were used in this study. Possible genomic DNA contamination was removed from total RNA using the DNAfree Turbo Kit (Ambion, Huntingdon, UK) and the first strand cDNA was prepared using the Mann-Whitney test was used to estimate the statistical significance of the differences in expression levels between cisplatin-treated and control samples. Results were considered to be statistically significant when P < 0.05.
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Cisplatin sensitivity
Sensitivity to the chemotherapeutic agent cisplatin was investigated in the five cells lines that constitute the NSCLC panel via clonogenic assay. Different susceptibilities to cisplatin were observed ( Fig. 1) , the most resistant cell line being A549 followed by H460, then H520 and finally H23. The cell line H522 was not capable of forming colonies under the conditions studied and therefore another method, cell counting, was used to assess the Table I) .
Cisplatin-induced cell cycle distribution changes and apoptosis
Analysis of the A549 and H460 cell cycle distribution in response to 50 µM cisplatin revealed that there was an abrupt accumulation of cells in the S-phase of the cell cycle by 10h
followed by a rapid increase in the number of cells in the G 2 and/or M phases by 24h, which then began to decrease by 48h (Fig. 3) . By 72h the percentage of cells in each phase of the cell cycle is clearly approaching the levels present in the control, indicating the cells were reestablishing the normal cell cycle distribution (Fig. 3) . A different effect was observed in H23, H522 and H520 cell lines, where there was a more gradual accumulation of cells in the S-phase over 24h -48h followed by an accumulation of cells in the G 2 and/or M phases that persisted at least until 72h (Fig. 3) . Generally, the cell cycle distribution of control samples Cisplatin-induced apoptosis results obtained by both flow cytometric assays (Annexin V-FITC/PI assay and Sub-G 1 peak detection) were in general accordance with each other and showed that only three of the five cell lines in the panel were undergoing apoptosis, namely H460, H23 and H522 (Fig. 4) . As expected, the most resistant cell line (A549) did not exhibit any cisplatin-induced apoptosis, whereas two of the three most sensitive cell lines had an elevated apoptotic index (H23 and H522). The high percentage of apoptotic cells observed in H460 cells was, however, somewhat unexpected considering that this is one of the most cisplatin-resistant cell lines.
Cisplatin-induced gene expression changes
Gene expression changes induced at 10h after cisplatin treatment were studied by (Table II) . The Microarray data were validated by analysing the expression levels of nine genes by real-time QRT-PCR (supplementary Fig. 2 ).
Cisplatin-induced gene expression changes were subsequently studied for eleven genes, in all cell lines that constitute the NSCLC panel, by real-time QRT-PCR. Six genes (p21, Gadd45α, XPC, DDB2, Fas and Bax) were selected because they were up-regulated in the A549 cell line in response to cisplatin as shown in the Microarray experiment, and another five genes because they are believed to be involved in cisplatin resistance (ERCC1, BRCA1,
CSA, MLH1 and Bcl2).
The results obtained by real-time QRT-PCR (Table III) (Table III) . Additionally, the up-regulation of P21, Bax, XPC and the down-regulation of Bcl2 were confirmed at the protein level in both cell lines by Western blotting analysis (supplementary Fig. 3 ).
The H522 cell line, of intermediate sensitivity, showed statistically significant upregulations in the transcription of p21 (at all incubation periods studied), DDB2 and BRCA1
(at 24h) and also a down-regulation in Bcl2 at 6 and 10h (Table III) . In the most sensitive cell line, H23, we only observed a 2-fold down-regulation in Bcl2 at 6h after cisplatin treatment, with the transcription of this gene appearing to return to control levels by 24h. The transcription of the DNA repair gene BRCA1 and of the pro-apoptotic gene Fas was only slightly up-regulated at 24h following cisplatin and those changes are probably not biologically significant. Of the cell lines tested, the H520 is the only one that did not seem to exhibit biologically significant changes in the expression of any of the genes studied (Table   III ).
The NSCLC cell lines could therefore be divided into two groups according to their transcriptional response to cisplatin, with the first group (A549 and H460) showing earlier and increased transcriptional response than the second (H23, H522 and H520).
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Discussion
Correlation between cisplatin-induced crosslink formation and/ or repair and cell survival
There was an inverse correlation between sensitivity to cisplatin and crosslink formation in vitro, in which the most sensitive cells were the ones with the lowest levels of crosslinks being formed, and an inverse correlation between cisplatin resistance and repair efficiency, in which the most resistant cell lines were the ones repairing crosslinks least efficiently. These results were somewhat unexpected considering that cisplatin cytotoxicity is believed to be due to DNA crosslinking 23 . The possibility that the most cisplatin-resistant cells from the NSCLC panel are able to tolerate/bypass the induced DNA lesions and continue performing their cellular functions (e.g. replication) provides an explanation to the observed results. A second possibility is that the more cisplatin-sensitive cells are indeed repairing the damage, as seen by the 'excision' of DNA crosslinks, but that they might not be repairing the DNA damage with high fidelity. Consequently, this 'mis-repair' could prove to be lethal at later times. In support of our findings, this lack of correlation between the level of DNA platination and sensitivity to cisplatin (at equimolar cisplatin doses) has been observed before [24] [25] [26] , indicating that sensitivity to cisplatin may not always be directly associated with DNA damage.
Cisplatin-induced cell cycle changes and damage tolerance
In terms of cisplatin-induced cell cycle variations, the panel of NSCLC cell lines could be clearly divided into two groups: A549 and H460 cell lines arrested their cell cycle at earlier time-points and recovered from it by 72h, whereas the other cell lines (H23, H522 and H520)
showed cell cycle arrest at later time-points and remained arrested by 72h (Fig. 3) . Taking into account the results presented in Fig. 2 , it is possible that the most resistant cell lines tolerate higher levels of cisplatin-induced crosslinks because they are able to re-enter the cell cycle despite the high level of DNA damage still present in their DNA at 72h. In contrast, the cisplatin-sensitive cell lines continue in their effort to repair the damage via prolonged cell cycle arrest. In fact, the analysis of cisplatin-induced cell cycle changes seems to be a good indicator of drug-resistance, as the more cisplatin-resistant cell lines are able to recover from cell cycle arrest and the more sensitive cells are not. Our results support the view that 14 increased tolerance to cisplatin adducts constitutes one of the possible mechanisms of resistance to cisplatin 27 .
Cisplatin-induced apoptosis and sensitivity to cisplatin
From the cell survival results, it would be expected for the most cisplatin-resistant cells of the NSCLC panel to exhibit less cisplatin-induced apoptosis than the more cisplatinsensitive cell lines. This was indeed the case for the most resistant cell line (A549), in which no cisplatin-induced apoptosis was detected, and for two of the most sensitive cell lines (H23 and H522), which undergo prominent apoptosis as a result of the cisplatin treatment.
However, it is difficult to understand why the H460 cell line, which is the second most cisplatin-resistant, after A549, has a higher percentage of cells undergoing apoptosis than all of the more cisplatin-sensitive cell lines (H522, H520 and H23). One hypothesis is that even though this cell line has increased cisplatin-induced apoptosis, the fewer cells that manage to survive proliferate more than the surviving cells of the most sensitive cell lines. This is supported by the fact that H460 cells still exhibit some cell growth at a cisplatin concentration of 50 µM, even at 72h after treatment (data not shown). It is thus possible that, at later incubation times, the H460 cells are able to recover from that initial high percentage of apoptosis, which could explain the fact this is the second most resistant cell line of the panel in the clonogenic assay. Indeed, the accelerated repopulation of tumours by surviving cells during chemotherapy is an important cause of treatment failure 28 . This accelerated repopulation in H460 cells could be due to the presence of a higher percentage of cancer stem cells in this particular cell line.
Cisplatin-induced gene expression in A549 as determined by Microarray technology
The apoptosis-related genes that were significantly up-regulated include the p53-regulated pro-apoptotic genes Fas 29 , TRAF4 30 , Bax 31 , TP53I3, 32 and PMAIP1, which is a mediator of DNA damage-induced apoptosis 33 . Interestingly, the Pim-2 gene, an inhibitor of apoptosis 34 , was also up-regulated indicating that there are conflicting apoptotic signals being up-regulated in response to this agent.
Genes involved in cell cycle and/or proliferation processes that were up-regulated include p21 and Gadd45α (p53-regulated genes) which are responsible for the up-or downregulation of several genes involved in cell cycle arrest and DNA repair 35 . Other p53-regulated genes whose expression was up-regulated in response to cisplatin include the cyclins G1 and G2 (involved in cell cycle arrest), the anti-proliferative BTG2 gene, which is also important in DNA damage response 36 , and the PPM1D gene 37 . Interestingly, the latter gene also possesses negative feedback effects on p53 activity thus functioning as a positive regulator of cell proliferation and being able to rescue cells from apoptosis 38 . This could possibly explain why these cells do not undergo cisplatin-induced apoptosis even though several pro-apoptotic genes are being up-regulated.
Cell cycle regulation genes that were down-regulated in response to cisplatin include CDC20, whose protein is required for nuclear movement prior to anaphase and chromosome separation 39 , and PLK1, a regulator of cell cycle progression that is essential for mitotic entry following recovery from DNA damage 40 . In addition, PLK1 functions as a p53 inhibitor, being capable of influencing not only cell cycle progression but also apoptosis in response to DNA damage 41 . These results give some indication of the mechanisms that may be causing the observed cisplatin-induced cell cycle arrest in this cell line.
Two DNA repair genes were up-regulated in response to cisplatin, XPC and DDB2.
XPC is a DNA damage-inducible NER gene whose protein has been shown to have an important role in the cisplatin-mediated cell cycle arrest and apoptosis 42 . DDB2 is also involved in the NER pathway and the transcription of both these genes is known to be regulated by p53 43, 44 . These two observations suggest that these cells may be starting to upregulate cisplatin lesion repair by NER, which was in fact observed in the comet assay data.
Transcriptional response to cisplatin, correlation with cell cycle arrest, apoptosis and
DNA damage formation and repair
Cisplatin treatment resulted in transcriptional activation of several apoptotic, DNA repair and cell cycle regulator genes. Again, the panel of NSCLC cell lines could be divided into two groups according to their transcriptional response (A549 and H460 with earlier and increased transcriptional response when compared to the other cell lines), which probably results from the differences in terms of p53 status. In fact, A549 and H460 cells are p53 wild type 45 , which explains the elevated induction of p53-responsive genes in these cell lines but not in the p53 mutated cells (H23, H522 and H520) 45, 46 . The latter cell lines do however show elevated expression of certain p53-regulated genes (e.g. p21, DDB2), which is most likely happening via a p53-independent pathway, e.g. 47, 48 .
Cell cycle arrest genes (p21 and Gadd45α) were up-regulated in the two most cisplatin-resistant cell lines (A549 and H460), which agrees with the observed induction of cell cycle arrest by cisplatin in these cell lines. The fact that the other three cell lines only showed mild or no up-regulation of these genes can be a direct consequence of them being p53 negative. However, it is important to bear in mind that whilst the transcriptional response was only studied up to 24h, the majority of the cell cycle arrest in the most sensitive cell lines (H23, H522 and H520) takes place at later time-points; so it is possible that the up-regulation of certain cell cycle arrest genes would be further pronounced at later incubation periods.
In terms of apoptosis induction, it is interesting to observe that the most cisplatinresistant cell line (A549) does not undergo apoptosis at any of the time points studied even though this agent causes the up-regulation of the pro-apoptotic genes Fas and Bax, and the down-regulation of the anti-apoptotic Bcl2 gene. In addition, cisplatin has been shown to upregulate protein expression of Bax and down-regulation of Bcl2 in this cell line which seems to indicate that there is a good correlation between transcriptional and translational response, at least for these two proteins. These observations seem therefore to indicate that this cell line has a defect in the apoptosis pathway downstream of these genes/proteins. Additionally, the translational response might be counteracted by other factors that inhibit the induction of apoptosis and that were not measured in this particular study. Conversely, the H460 cell line,
the second most resistant, shows high cisplatin-induced up-regulation of pro-apoptotic genes (and proteins) and subsequent extensive cisplatin-induced apoptosis.
Genes involved in DNA damage recognition and repair that were shown to be upregulated in response to cisplatin include XPC, DDB2 and ERCC1. This only occurs in the most cisplatin resistant cells (A549 and H460), indicating that they are attempting to respond to the cisplatin insult by increasing the repair of the DNA lesions, which is in fact verified by the comet assay (Fig. 2) . However, the comet assay data also showed that H23, H522 and H520 were more efficient at repairing the cisplatin-induced crosslinks than A549 and H460 cells, which seems to be independent of the transcriptional up-regulation of the XPC, DDB2
and ERCC1 genes. Nevertheless, it is necessary to bear in mind that only the mRNA levels were studied and these may not always correlate with the levels of the respective functional proteins.
Our results show that the most cisplatin-resistant cell lines, A549 and H460, were the ones exhibiting higher crosslink levels and lower repair efficiency, a more transient cell cycle arrest and greater cisplatin-induced variations in the expression of the genes under study.
However, it could be that the more sensitive cell lines take longer to react to the cisplatin insult and this is the reason why delayed and/or fewer responses were detected.
Conclusions of the study and implications for predictive testing
Overall, the results discussed above suggest that lesion tolerance ( Additionally, the fact that different assays generated different ranks of sensitivity/resistance to the chemotherapeutic agent studied here (Supplementary Table II) indicates the pitfalls of attempting to predict outcome based on the measure of a single end- α-Tubulin, 55kDa
